Tamoxifen: Using pharmacogenetics to rediscover an old drug

Tamoxifen can be considered a classic 'pro-drug', requiring metabolic activation to elicit pharmacological activity. Our findings suggest that both genetic and drug-induced factors that alter CYP2D6 enzyme activity influence the clinical response to tamoxifen. Given the small differences in disease-free survival comparing tamoxifen to third-generation aromatase inhibitors, knowledge of the genetic and environmental factors that influence CYP2D6 enzyme activity may provide a robust tool to individualize the hormonal therapy to breast cancer. © 2007 Cambridge University Press.

Duke Scholars

Author Arif H Kamal Medicine, Medical Oncology